平衡过渡和再录取:对低剂量与标准布普伦诺芬开始进行医学管理的阿片类药物戒断的比较研究
Tara Nichols1, Sean T Lynch2, Emily Groenendaal3
1New York Medical College, School of Medicine, Department of Psychiatry and Behavioral Sciences.
Journal of addictive diseases
|March 3, 2026
概括
针对阿片类药物使用障碍 (OUD) 的低剂量启动 (LDI) 和标准剂量启动 (SDI) 的布普伦诺芬 (BUP) 显示了类似的住院结果. LDI与更少的一年再入院有关,这表明在芬太尼时代,这两种药物都是可行的.
科学领域:
- 成 药物 药物 药物 药物
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 芬太尼的增加复杂化了阿片类药物使用障碍 (OUD) 的布普伦诺芬 (BUP) 启动.
- 急性戒断是标准剂量启动 (SDI) 的重大风险.
- 低剂量启动 (LDI) 被探索以改善 BUP 治疗耐受性和参与度.
研究的目的:
- 为了比较LDI与SDI的住院和出院后的结果.
- 评估不同布普伦诺芬启动策略在医疗管理戒断中的有效性.
主要方法:
- 对经过医疗管理的OUD戒断的成年人进行回顾性队列研究.
- 相比的SDI (2020年2月-2021年4月) 和LDI (2021年5月-2022年8月) 组.
- 分析了住院时间,BUP接受,出院剂量,康复过渡,再入院和门诊参与.
主要成果:
- 在LDI和SDI之间,在住院时间,BUP接受或出院剂量方面没有显著差异.
- 在LDI组显示明显较低的一年再录取的几率.
- 释放后BUP补充和门诊出院率在各组之间是相似的.
结论:
- 低剂量启动 (LDI) 和标准剂量启动 (SDI) 显示了OUD戒断管理的可比结果.
- LDI与长期再录取减少有关.
- 在当前的治疗环境中,LDI和SDI都是布普伦诺芬启动的可行策略.
相关概念视频
Drug Dependence
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
IV Infusion to Oral Dosing: Conversion Methods
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...


